About Us  |  Contact Us  |  Español
Woman And Infants
Leapfrog Group Top Hospital Designation
Woman And Infants

Press Release

Targeted Way to Treat Ovarian Cancer Discovered
02/19/2014

Researchers at Women & Infants Hospital of Rhode Island have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while being resistant to chemotherapy. This would improve treatment and survival rates for some women.

The work coming out of the molecular therapeutic laboratory directed by Richard G. Moore, MD, entitled "HE4 (WFDC2) gene overexpression promotes ovarian tumor growth" was recently published in the international science journal Scientific Reports, a Nature publishing group.

"We have known that the protein HE4 is present in women who have ovarian cancer," says Moore, who created the Risk of Ovarian Malignancy Algorithm (ROMA) to determine if a pelvic mass is cancerous based on the levels of HE4 and another protein. "What no one knew was why the protein is there or what activates it."

The WFCD2 gene produces a "messenger RNA" that encodes for the HE4 protein, not only imparting an aggressiveness to the tumor, enabling it to grow quickly, but also conveying a resistance to chemotherapy drugs used to treat the tumor.

"It plays a part in allowing the cancer to grow without restriction," Moore says. "We have determined that HE4 plays a part in allowing ovarian cells to become cancer cells, giving them the ability to grow and resist chemo."

Once they identified the function of the protein, Moore's research team was able to design a biologic drug that can prevent the messenger RNA gene from creating HE4. The novel biologic has been tested in cell and animal models, and the results are that the cancer does not grow as aggressively and responds to chemotherapy.

"We would give this biologic – which has minimal side effects – to any patient we identify through a blood test as producing HE4," he says, adding that oncologists have recognized that women with high levels of HE4 do not respond to treatment and their survival rates are lower. "This would be an individualized treatment that could increase survival rates of some women with ovarian cancer."

Moore and his team will continue testing the biologic drug, preparing for clinical trials in humans.

"This is a tremendous discovery and could mean the difference between life or death for some women with ovarian cancer," says Maureen G. Phipps, MD, MPH, chief of obstetrics and gynecology at Women & Infants. "Dr. Moore's research is ground-breaking in the area of ovarian cancer, and it's all happening in his laboratory in the Knowledge District of Providence."

About Women & Infants Hospital

Women & Infants Hospital of Rhode Island, a Care New England hospital, is one of the nation's leading specialty hospitals for women and newborns. The primary teaching affiliate of The Warren Alpert Medical School of Brown University for obstetrics, gynecology and newborn pediatrics, as well as a number of specialized programs in women's medicine, Women & Infants is the eighth largest stand-alone obstetrical service in the country with nearly 8,400 deliveries per year.In 2009, Women & Infants opened the country's largest, single-family room neonatal intensive care unit.

New England's premier hospital for women and newborns, Women & Infants and Brown offer fellowship programs in gynecologic oncology, maternal-fetal medicine, urogynecology and reconstructive pelvic surgery, women's mental health, neonatal-perinatal medicine, pediatric and perinatal pathology, gynecologic pathology and cytopathology, and reproductive endocrinology and infertility. It is home to the nation's only mother-baby perinatal psychiatric partial hospital, as well as the nation's only fellowship program in obstetric medicine.

Women & Infants has been designated as a Breast Center of Excellence from the American College of Radiography; a Center for In Vitro Maturation Excellence by SAGE In Vitro Fertilization; a Center of Biomedical Research Excellence by the National Institutes of Health; and a Neonatal Resource Services Center of Excellence. It is one of the largest and most prestigious research facilities in high risk and normal obstetrics, gynecology and newborn pediatrics in the nation, and is a member of the National Cancer Institute's Gynecologic Oncology Group and the National Institutes of Health's Pelvic Floor Disorders Network.

Back
banner_parentclass_210
banner_qanda_210
Woman And Infants
© 2011 Site Index | Disclaimer | Legal Notices | Talks Your Health